Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

24 May 2025

Abstract excerpt

Ruxolitinib is a potent JAK1/JAK2 inhibitor, approved for the treatment of primary myelofibrosis (PMF) patients based on the concept of inhibition of oncogenic signaling. However, the effect of ruxolitinib on JAK2-V617F allelic burden is modest, suggesting that inhibition of JAK2-V617F signaling-driven clone expansion is not the main mechanism of action. We evaluate whether ruxolitinib mainly blocks the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40413183
DOI: 10.1038/s41467-025-60019-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingPMID 40413183Read ↗

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.Semantic proximity Read ↗

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?Semantic proximity Read ↗

Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Semantic proximity Read ↗

Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.Semantic proximity Read ↗

Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.Semantic proximity Read ↗

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasmsSemantic proximity Read ↗

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read ↗

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Loss of Function Mouse Models Reveal a Novel Regulatory Function for ULK1 in Myeloproliferative Neoplasms.Semantic proximity Read ↗

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Semantic proximity Read ↗

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.